Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Moderna, Inc. - MRNA

Ginkgo Bioworks Holdings

Cassava Sciences Inc

The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more.

3 Biotech Stocks to Sell in July Before They Crash & Burn

Illumina

Thermo Fisher Scientific

When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and overall DNA repair.

3 Biotech Stocks Turning DNA Dreams Into Dollars

Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.

Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine

Moderna (MRNA) shares edged higher Tuesday after the biotech firm received a federal grant to develop a vaccine to prevent bird flu in humans.

Moderna Receives HHS Grant to Develop a Bird Flu Vaccine

The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in dairy cows and infections of three dairy workers since March.

US awards Moderna $176 million to produce bird flu vaccine

Moderna Inc.'s efforts to develop a bird-flu vaccine are getting a boost from the U.S. government, the company said Tuesday.

Moderna gets U.S. government funding for bird-flu vaccine development

Moderna has secured $176 million in federal funding to develop mRNA vaccines against a potential bird flu pandemic, the Boston-based company announced Tuesday, a move that could bolster U.S. vaccine stockpiles as health officials and experts worry the highly contagious H5N1 influenza virus tearing through poultry farms and cattle herds could spread to humans.

Moderna Scores Federal Funding For mRNA Bird Flu Vaccine As Pandemic Fears Grow

CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

Pfizer

London's High Court on Tuesday ruled that one of Moderna's patents relating to technology key to the development of vaccines for COVID-19 was invalid, but that another was valid and had been infringed by Pfizer and BioNTech's rival vaccine.

UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case

If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.

CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine

There is no evidence of major birth defects in babies born to mothers vaccinated against COVID-19 during the first trimester of pregnancy, according to new research published in JAMA Pediatrics on Monday, underscoring the safety of vaccination during pregnancy amid mounting evidence of the severe health risks infections can cause for mothers and babies.

Pfizer And Moderna Vaccines Not Linked To Birth Defects, Study Finds

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

Investors Who Lost Money on Moderna, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MRNA

GlaxoSmithKline

The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.

CDC Narrows Age Recommendation for Use of RSV Vaccine

Intellia Therapeutics

Recursion Pharmaceuticals

Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.

Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet

NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

An Investigation Has Commenced on Behalf of Moderna, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRNA Losses

The vaccine has already won approval from the FDA

Moderna's RSV vaccine gets positive opinion from EU advisory panel

CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Following the CHMP's positive opinion, the European Commission will adopt a decision on the authorization of mRESVIA.

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna's RSV Vaccine, mRESVIA(R)

Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.

Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

Moderna recently won approval for a second product -- one with a $10 billion market. Pfizer offers a juicy dividend yield and better growth prospects than you might think.

2 Stocks Down More Than 30% to Buy Right Now

GSK PLC (LSE:GSK, NYSE:GSK) shares fell 6% after US authorities recommended restrictions on doses of any respiratory syncytial virus (RSV) vaccine. Pfizer and Moderna, which also make RSV vaccines, fell 2% and 11% in New York overnight.

GSK and Moderna slide on RSV vaccine CDC updates

Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

ATTENTION Moderna, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.

Why Is Moderna Stock Trading Lower On Wednesday?

Moderna Inc.'s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.

News for Moderna Stock (MRNA)